By JOHN SAMARAS
Ask what Ozempic costs. The honest answer runs from $25 a month to $1,100 a month, and every number in that range is real, published, and defensible. A phrase that covers a forty-four-fold spread is not a price. It is a fog, and patients make four-figure annual decisions inside it.
I run GLP Chart, an independent GLP-1 price index. The index shows that “the price of Ozempic” fails as a concept for three stacked reasons. The molecule sells in five forms under four names. Each form sells through different channels at different prices. And the advertised price rarely survives to month four.
One molecule, five forms
Ozempic is semaglutide, branded for type 2 diabetes. The same molecule is Wegovy when approved for weight loss, sold as a weekly pen and, since 2026, a daily pill. It is Rybelsus in the older oral form. And 503A compounding pharmacies still sell it as compounded semaglutide where the rules allow, though the FDA’s compounding restrictions and the manufacturer lawsuits thinned that market through 2025 and 2026.
When someone says “Ozempic price,” they almost always mean “what will semaglutide cost me.” Those are different questions with different answers.
Same molecule, seven prices
Here is the current board from our price index. Every cash figure comes from the seller’s own published pages. The last two rows are copays.
Every row is “the price of Ozempic” in somebody’s mouth.
One row is worth a second look. Novo Nordisk cut its own direct-to-consumer pen price from $499 to $349 in November 2025, a 30 percent cut. The pharmacy-counter price above did not move. The gap between those two rows is not a market inefficiency. It is the business model.
The membership layer
A telehealth program that prescribes the Wegovy pill routes you to the same $299 NovoCare price you could get yourself. What the program adds is a membership fee, $74 to $149 a month across the programs we track, covering the prescriber, the app, and refill logistics. Whether that fee buys anything you need is a fair question, and it is a different question at $74 than at $149.
Two design choices in this layer deserve more attention than they get, because they work together.
First, starter-dose pricing. The pill that costs $149 in month one costs $299 at the dose you will actually stay on.
Second, lock-ins. Eight of the 29 programs we track commit patients to a contract, three of them for a full year. A teaser price plus a contract is a retention machine, not a discount.
The pricing is also granular enough that even the sellers engage with it line by line. This week, Ro’s communications team wrote to flag that an annual prepaid medication plan cuts their Wegovy pill price to $249 a month. They were right. Their published pricing page confirms it, and our listing now says so. It takes that level of specificity to state one program’s one price for one form of one molecule. “The price of Ozempic” was never going to survive contact with this market.
What to check before paying anything
Five questions, in order:
“The price of Ozempic” will keep showing up in headlines because it is short. But it hides the two numbers that decide whether treatment is affordable: the maintenance-dose total after the teaser expires, and the fee stack on top of the medication. Name the form, name the channel, name the month. Then you have a price.
John Samaras is the founder and editor of GLP Chart, which tracks what every major GLP-1 program charges, checked every Monday, with the methodology public. No program pays to be listed or ranked.
